NetTargets employs an AI system that combines multi-omics data with neural network modelling for drug discovery.

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.